Rapid Communication

Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets

Doron Bresler1,5, Jan Bruder2, Klaus Mohnike3, William D Fraser4 and Peter S N Rowe5

1United States Air Force (USAF) Lackland, San Antonio, Texas, USA
2University of Texas Health Science Center at San Antonio, Dept of Medicine, Floyd Curl Drive, San Antonio, Texas 78229, USA
3Otto-von-Guericke Universität, Magdeburg, Zentrum f. Kinderheilkunde, Germany
4University of Liverpool, Department of Clinical Chemistry, Royal Liverpool University Hospital, Liverpool, United Kingdom
5University of Texas Health Science Center at San Antonio, Dept of Periodontics, Floyd Curl Drive, San Antonio, Texas, 78229, USA

Abstract

MEPE (Matrix Extracellular Phosphoglycoprotein) expression is markedly elevated in X-linked-hypophosphatemic-rickets (HYP) and tumor-induced osteomalacia (TIO). In normal individuals, circulating serum-levels of MEPE are tightly correlated with serum-phosphorus, parathyroid hormone (PTH) and bone mineral density (BMD). Also, MEPE derived, C-terminal ASARM-peptides are candidate minhibins and/or phosphatonin. Our aims were to determine: 1. whether MEPE-ASARM-peptide(s) are abnormally elevated in HYP/hyp serum, and, 2. whether the ASARM-peptide(s) accumulate in hyp mice kidney renal tubules. Using a specific competitive ELISA we measured a five fold increase (P=0.007) of serum ASARM-peptide(s) in human HYP patients (normal subjects 3.25 µM, n=9; S.E.M.=0.51 and HYP-patients 15.74 µM, n=9; S.E.M.=3.32). A 6.23 fold increase (P=0.008) was measured in hyp male mice compared with their normal male siblings (normal-siblings, 3.73 µM, S.E.M.=0.57, n=3; and hyp-mice 23.4 µM, n=3, S.E.M.=4.01). Renal immuno-histological screening also revealed a dramatic increase of ASARM-peptides in regions anatomically consistent with the proximal convoluted tubules. This study demonstrates for the first time that markedly elevated serum levels of protease-resistant ASARM-peptide(s) occur in HYP/hyp and they accumulate in murine hyp kidneys. These peptides are thus likely responsible for the phosphaturia and defective mineralization in HYP/hyp and TIO.


Introduction

Seufert et al. 2001, Shimada et al. 2001). MEPE has also been shown to be phosphaturic in vivo and in vitro and inhibits mineralization in vitro (Dobbie et al. 2003, Rowe et al. 2004b). The levels of MEPE in normal serum (476 +/- 247 ng/ml) are tightly correlated with serum PO4, PTH and bone mineral density (Jain et al. 2004). MEPE expression is also suppressed by 1,25 vitamin D3 (Argiro et al. 2001). Direct administration of recombinant MEPE increases 1,25 vitamin D3 serum levels (Rowe et al. 2004b) and vitamin D receptor null-mutants (VDRKO) have increased expression of MEPE (Okano et al. 2003, Rowe et al. 2004b). Moreover, MEPE expression is tightly correlated with FGF-23 expression a known mediator of changes in vitamin D metabolism, mineralization and renal phosphate handling (Liu et al. 2003).

This combination of biochemical and physiological features suggests that MEPE and/or MEPE processed peptides play major roles in the pathophysiology of HYP and TIO. Further support for this hypothesis is the finding that PHEX protects MEPE from proteolysis in vitro (Guo et al. 2002). Moreover, using surface-plasmon-resonance (SPR) technology, we have also shown that MEPE forms a specific, Zn-dependent protein–protein interaction with PHEX via the MEPE C-terminal ASARM-motif (Rowe et al. 2004a). We have proposed that the well documented elevated protease levels in hyp and loss of sequestration by mutated PHEX will result in an increase in protease-resistant free ASARM-peptide levels (Rowe 2004, Rowe et al. 2004a, Rowe et al. 2004b). The elevated serum ASARM-peptide levels in turn will inhibit mineralization and renal phosphate handling.

Thus, the evidence clearly supports the potential pathophysiological role of the free ASARM-peptide in HYP and TIO. However, it is not known whether the relative serum levels of ASARM-peptide(s) are actually elevated in these diseases. In this paper, we present evidence for the first time that confirms markedly elevated serum ASARM-peptide in humans and mice affected with X-linked hypophosphatemic rickets. Moreover, the levels are entirely commensurate with the amounts of peptide required to seriously impact mineralization and renal phosphate handling (Rowe et al. 2004a, Rowe et al. 2004b). Also, renal immunological staining of hyp mice kidneys revealed an unequivocal increase in ASARM-epitope staining of anatomical structures consistent with the proximal convoluted tubules in hyp mice relative to normal littermates. These new findings will hopefully be of use for the design of new regimes for the clinical management of HYP, TIO, renal disease and diverse bone-mineral loss disorders.

Materials and Methods

Serum samples

Serum from families with X-linked hypophosphatemic rickets (HYP), from affected and non-affected individuals were previously described and obtained under approved IRB protocols (HYP-consortium et al. 1995, Rowe et al. 1994, Rowe et al. 1996, Rowe et al. 1997). All clinically affected members had fully characterized mutations in the PHEX gene and as previously described were part of a data-set originally used to map and clone the HYP gene. Sera from nine affected HYP patients (three affected males (hemizygous), and six females) and nine normal subjects (five male and four females) were analyzed. Hyp mice were purchased from the JAX laboratories (Bar Harbor, ME, USA) with the mutation bred into a C57BL6 background. Standard PCR and southern genotyping was used to confirm hyp phenotypes (Strom et al. 1997). The sera from six male hyp mice, three affected (hemizygous) and three normal individuals were used in this study.

MEPE-ASARM-peptide (phosphorylated and non-phosphorylated) and polyclonal antibodies

The carboxy terminal region of MEPE containing residues 507–525 were synthesized using routine techniques by multiple peptide cloning systems (Multiple Peptide Systems, San Diego, CA). For ELISA studies, both phosphorylated and non-phosphorylated peptides were synthesized. The phosphorylated form of the peptide \( \text{NH}_2-\text{RDDSSESSDSG(Sp)S(Sp)E(Sp)DGD-COOH} \) was biotinylated using a Pierce EZ-Link Sulfo-NHS-LC-Biotinylation Kit and the peptide de-salted using an Amersham Biosciences PD-10 desalting column. Both phosphorylated and non-phosphorylated peptides were equally effective in competition assays and the non-phosphorylated form was routinely used to generate standard curves (see Fig. 1A and B). Rabbit polyclonal antibodies raised against ASARM-peptide \( \text{NH}_2-\text{CFSS RRRDSESSEDGSSGESDGD-COOH} \) were used in these studies and have been previously described (Rowe et al. 2004b). Pre-immune sera from the same rabbits were used as negative controls.

ELISA assay

A new enzyme-linked-immunosorbet-assay (ELISA) was designed to specifically quantitate ASARM-peptide(s) in sera from humans and mice. The important components of this assay included 96 well Reacti-Bind Protein–G Coated Plates (Pierce & Co), anti-ASARM-peptide polyclonal antibody (see above), non-phosphorylated ASARM-peptide (also described above), a biotinylated ASARM-peptide (bio-ASARM-peptide), streptavidin horseradish-peroxidase conjugate (Zymed Laboratories, Inc., South San Francisco, CA), and an ECL Advance chemiluminescent detection kit (Amersham BioSciences, Piscataway, NJ). The overall rationale behind the ELISA was briefly as follows. Initially, the Protein–G–immobilized 96 well plates were used to specifically bind anti-ASARM-IgG antibodies. Synthetic bio-ASARM-peptide
was then bound specifically to the immobilized ASARM-antibodies and streptavidin conjugated to horseradish-peroxidase was then allowed to bind to the biotin of the bio-ASARM-peptide. The highly sensitive ECL reagent light-emission system (Amersham Biosciences) was then used to generate a horseradish-peroxidase catalyzed light-signal. The light-signal was in turn detected by a highly sensitive BioRad FluorImaging system camera (-40°C, peltier-cooled, 1340 × 1040 pixel CCD resolution, CCD digital-camera). Quantitation of chemiluminesence was carried out using Quantity-1, Bio-Rad, imaging-software. Pixel saturation was prevented by internal software-calibration and exposure adjustment. All light-emission readings were thus accurately quantitative and non-saturating. Pre-incubation of bio-ASARM-peptide with increasing amounts of synthetic non-biotinylated ASARM-peptide prior to addition to plates coated with protein-G-anti-ASARM antibody resulted in a peptide competition for binding to the immobilized anti-ASARM-peptide polyclonal IgG. This in turn resulted in a quenching of the chemiluminescent signal as a function of increasing amounts of non-biotinylated ASARM-peptide in the presence of a constant amount of bio-ASARM-peptide. Maximum chemiluminescence (0% quenching) was achieved in the absence of non-biotinylated peptide (full bio-ASARM-peptide mediated light-signal emission) and maximum quenching (100%) was achieved in the presence of excess non-biotinylated ASARM-peptide (reduced light emission and binding of bio-ASARM-peptide). Pre-immune serum was also used as a negative control (zero chemiluminescence). Thus, maximum light or 0% quenching indicates low levels of standard synthetic ASARM-peptide or ASARM-peptides in the experimental unknown, and, low-light emission or maximum quenching (100%) is indicative of high concentrations of ASARM-peptide. The following describes the experimental protocol in more detail.

First, to block non-specific binding, 40 µl of Tris-buffered saline (TBS) supplemented with 0.1% (v/v) Tween-20, and 5% non-fat dried skimmed milk (TBST-M; Amersham-Biosciences CAT No: RPN2125V) was added to each well of 96 well Protein G coated plates and then incubated at 5°C with shaking overnight. Plates were then washed three times with the same buffer but without the non-fat dried skimmed milk (TBST). After washing with TBST, 40 µl of a 1:4000 dilution of anti-ASARM antibody was added to each well (diluted in TBST-M). Plates were then incubated at room temperature for 1 h to facilitate binding of anti-ASARM IgG antibodies to plate-immobilized protein-G. Plates were then washed three times with a TBST. The competition assay was then carried out by separately mixing a constant 0.5 ng/ml concentration of bio-ASARM-peptide with differing concentrations of non-biotinylated ASARM-peptide standards (standard curve) or a range of dilutions of sera as discussed in results and shown in Fig. 1A and B. All dilutions were made using the TBST buffer. For competition with a 0.5 ng/ml bio-ASARM-peptide the following standard concentrations of non-biotinylated ASARM were optimal: 250, 187, 125, 93, 60, 30, 15 and 7.5 ng/ml (Fig. 1). Both pre-immune sera and excess non-biotinylated ASARM (1 µg/ml) were used as separate negative controls (zero chemiluminescence). The competition solutions (40 µl) were then added to individual wells of the 96 well plate containing immobilized anti-ASARM-IgG and left for 1 h at room temperature. Plates were then washed three times with TBST solution. Forty micro-liters of a 1:20 000 dilution of streptavidin horseradish peroxidase conjugate in TBST was then added to each well and incubated for 25 min at room temperature. The plate was washed a further three times with TBST and then directly developed with ECL plus-Advance chemiluminescence kit reagents (Amersham Bioscience). The plate was then left to incubate for 5 min in the dark and reagents removed from each well prior to chemiluminescence detection by the FluorImager camera (BioRad). Spiking of sera with non-biotinylated ASARM-peptide was also carried out to determine recovery.

**Immunohistochemistry of renal sections using anti-ASARM-peptide polyclonals**

Mice (three hyp male mice and three normal male littersmates) were first anesthetized with metofane and cardiac exsanguination was used to remove blood for serum preparation using humane methods and protocols approved by IACUC and UTHSCSA. After exsanguination, left kidneys were then removed from mice and immediately preserved in Millonig’s phosphate buffered formalin (MPBF; Medical Industries Inc.). The collected and processed mice sera were used for ELISA analysis as described above. For immunohistochemical detection of ASARM-peptide epitopes, 3 µm thin sections prepared from paraffin-embedded kidneys were incubated with polyclonal anti-ASARM-peptide antibodies raised against the same MEPE C-terminal ASARM-peptide used for ELISA analysis (see above). The immunological reaction was visualized by an ABC alkaline phosphatase kit (Vector) and counter-stained with Mayer’s hematoxylin-eosin (Fig. 3). The effects of blocking the renal immuno-positive reactions were investigated by spiking the anti-ASARM-peptide polyclonal antibodies with excess ASARM-peptide (250 µM). Additional control renal sections were also screened with pre-immune antisera derived from the same animals used to raise the anti-ASARM-peptide polyclonals.

**Statistical analysis**

Differences were assessed statistically by the use of Newman-Keuls, Bonferroni multiple comparison equations after one-way analysis of variance (non-parametric)
or t-tests (as indicated). A P value of less than 0·05 was considered significant. The standard error of the mean (s.e.m.) was used as a representative measure of how far the sample mean differed from the true population mean. Quantity 1 Bio-Rad software was used to analyze the intensity of chemiluminescent light-emission of samples and this was captured by a Bio-Rad FluorMax digital imaging system and data incorporated into GraphPad Prizm-4 software (Graphpad software. Inc.), for statistical analysis.

Results

Competitive ELISA using biotinylated and non-biotinylated ASARM-peptides

A competitive ELISA method was used to measure the levels of ASARM-peptide epitopes in serum as described in methods. Fig. 1A and B show the results derived from standard competition experiments (6 experiments, each sample in triplicate) containing 0·5 ng/ml biotinylated peptide and increasing concentrations of non-biotinylated synthetic ASARM-peptide. In Fig. 1A, a one site binding hyperbola clearly demonstrates a classic increased quenching of chemiluminescence correlated with increasing amounts of non-biotinylated ASARM-peptide in the presence of a constant amount (0·5 ng/ml) of biotinylated peptide. A K_D of 7·5 ng/ml and a Q_max (quench maximum) of 98·7% was obtained. A plot of log_{10} transformation of concentrations against percent quenching (Fig. 1B) enabled a linear regression curve to be computed (P<0·0001 and r^2=0·9405). The linear range for ASARM-peptide assay was 10–200 ng/ml (4·8 to 95·2 nM). Spiking of serum samples with non-biotinylated ASARM-peptide confirmed a greater than 87% recovery of product.

Serum ASARM-peptides in human and mouse X-linked rickets (HYP/hyp)

Figure 2 graphically depicts log_{10} dilution-transformation linear regression results as an end-point histogram for both HYP patients and hyp mice. The levels of ASARM-peptide epitope are elevated 5 fold in human subjects affected with HYP (P=0·007) relative to normal subjects (3·25 µM normal; 15·74 µM HYP). The levels of ASARM-peptide are also dramatically elevated in hyp-mice but even more so with a 6·2 fold increase compared with normal male siblings (3·73 µM and 23·4 µM).

ASARM-peptide epitope elevated binding in hyp renal proximal convoluted tubules

Figure 3 shows a cross section of hyp mice and normal littermates renal cortex paraffin sections screened with MEPE anti-ASARM polyclonal antibodies. Immuno-positive staining was markedly more pronounced in the hyp renal sections relative to normals. Moreover the staining was localized to areas anatomically consistent with the proximal convoluted tubules. The glomeruli are also clearly visible in all sections but were not immuno-positive. The ASARM immuno-positive staining was
Discussion

This study confirms a marked elevation of serum ASARM-peptides in human subjects affected with X-linked hypophosphatemic rickets (HYP). Also, a similar elevation was observed in the murine homologue of X-linked rickets (hyp), specifically, in male hyp mice relative to their normal male littermates. Although the levels of ASARM-peptides were markedly elevated in both humans and mice affected with the disease the increase was greater in the hyp mice (5 fold in humans, 6/2 fold in mice). We speculate that this may be due to the fact that some of the human subjects were under treatment with calcitriol and phosphate supplements to counteract the disease. Calcitriol (1,25-vitamin D3) suppresses MEPE expression (Argiro et al. 2001, Okano et al. 2003, Rowe et al. 2004b) and thus may have indirectly contributed to a reduction in ASARM-peptide levels in the treated human patients.

The ASARM-motif is a potent inhibitor of mineralization (Long et al. 1998, Raj et al. 1992, Schwartz et al. 1992). Statherin is also thought to play a role in phosphate and calcium transport in the parotid glands and dentin mineralization dynamics. Remarkably this short salivary peptide maps to the same locality as MEPE on chromosome 4 in a region clustered with bone-dentin proteins (Rowe 2004, Rowe et al. 2004b). This group of proteins (osteopontin, DMP-1, BSP, DSPP, enamelin and MEPE) share many features and have been grouped in the SIBLING family (Fisher et al. 2001, Rowe 2004, Rowe et al. 2000). Osteopontin, DSPP, DMP-1 and MEPE also contain the ASARM-like motif and the fact that statherin maps to this region suggests an ancestral link between this important group of bone-dentin mineralization genes (Rowe 2004).

The ASARM-motif has distinct physicochemical and biological features that compare remarkably well with phosphonoformic acid (PFA) and also bisphosphonates (like etidronate). These molecules are small, highly charged, acidic with low pIs and phosphorylated. Both PFA and etidronate have dramatic effects on mineralization (inhibition) and renal phosphate, vitamin D metabolism and renal-phosphate uptake in vivo and in vivo (Loghman-Adham 1996, Loghman-Adham & Dousa 1992, Loghman-Adham et al. 1993, VanScyoy et al. 1988). Also PFA and etidronate bind to the renal Na-phosphate co-transporter (NPT2) and effect an inhibition of phosphate uptake (Loghman-Adham 1996, Loghman-Adham & Dousa 1992, Loghman-Adham et al. 1993, VanScyoy et al. 1988). In the case of PFA, dual effects
on phosphate uptake have been demonstrated and are thought to be due to the reversible and specific binding of this molecule (PFA) to the renal phosphate co-transporter (Loghman-Adham & Dousa 1992). In brief, chronic exposure and thus binding of PFA to the NPT2 transporter likely results in an increase in mobilization and expression of NPT2, but, the saturated levels of PFA continue to sterically interfere with transport function with consequential inhibition of phosphate transport. This is confirmed by the fact that in vitro, if repeated washes are administered to attached renal cells previously exposed to PFA, a reversal of inhibition occurs and an increase of phosphate uptake ensues (Loghman-Adham & Dousa 1992).

In this study we have demonstrated that ASARM-peptides are not only elevated in HYP/hyp but also for the first time demonstrate accumulation in the renal proximal convoluted tubules of hyp mice. This is consistent with the known phosphaturic effects of rec-MEPE in vivo and in vitro. Moreover this is also consistent with the known biological effects of PFA/etidronate and the shared physicochemical features with the ASARM-peptide.
The MEPE ASARM-peptide is a known inhibitor of mineralization as are other ASARM-motifs in molecules such as statherin and osteopontin (Bennick et al. 1981, Hoyer et al. 2001, Long et al. 1998, Raj et al. 1992, Rowe 2004, Rowe et al. 2004a, Rowe et al. 2004b, Schlesinger & Hay 1977). Moreover, the levels measured in HYP patient and hyp mouse serum are commensurate with the levels that would cause phosphaturia and an inhibition of mineralization (Rowe et al. 2004a, Rowe et al. 2004b). Thus we conclude that the ASARM-peptide plays a major role in the pathophysiology of HYP/hyp. Moreover, since HYP pathophysiology overlaps with TIO and MEPE tumor-expression is a feature of this tumor-induced disease, we would expect a similar elevation of ASARM-peptides in TIO. Preliminary data on one of our TIO patients indicates that this is indeed the case. However, this needs to be confirmed by a detailed analysis of a number of patients with TIO before and after resection of tumors. Also, given that serum MEPE levels and expression show tight correlations and associations with serum PO₄, PTH, bone mineral density, serum 1,25 vitamin D₃, PHEX and FGF-23 (Jain et al. 2004, Liu et al. 2003, Rowe et al. 2004b), a physiological role for MEPE in bone-mineral and renal-phosphate handling is likely.

A caveat must be included concerning the derivation of the ASARM-peptide(s) measured in these studies. Specifically, DMP-1, OPN, DSP and statherin contain the ASARM-motif and likely share epitopes with the MEPE-ASARM-peptide. Thus we cannot exclude the possibility that our anti-ASARM-peptide polyclons are wholly specific for the MEPE-ASARM-motif. However, given that MEPE expression is markedly elevated in HYP and is tightly correlated with serum PO₄, PTH, BMD, 1,25 vitamin D₃ and FGF23, the MEPE source of ASARM-peptide is likely predominant in serum. Also, our observations for the first time provide a compelling and novel link with the extracellular-matrix derived ASARM-peptide(s) and the dynamics of renal phosphate handling/bone–dental mineralization in disease and health.

Finally, we have recently demonstrated a specific non-proteolytic protein–protein association between MEPE and PHEX using surface plasmon resonance technology (Rowe et al. 2004a). Moreover, SPR peptide competition experiments confirm that the carboxy-terminal ASARM-motif plays a key role in this Zn–dependent interaction. N-terminal, mid-region RGD-MEPE peptides and control peptides were unable to inhibit the PHEX-MEPE interaction. Thus we conclude that PHEX may act by sequestering and protecting MEPE from proteolysis and thus preventing release of free protease-resistant ASARM-peptide. In HYP/hyp, defective PHEX, elevated proteases and increased expression of MEPE result in increased ASARM-peptide with deleterious consequences to mineralization of bone and renal phosphate handling. These experiments for the first time confirm that these peptides are indeed elevated in HYP/hyp and this in turn provides compelling evidence for the ASARM-model in disease and health (Rowe 2004, Rowe et al. 2004a, Rowe et al. 2004b).

Acknowledgements

We thank Mr Brandon Selleke for his technical assistance with the renal immuno-histology slides. We are also indebted to the support provided by the following National Institutes of Health (NIH) grants to P S N R: 1R03DE015900–01 (National Institute of Dental & Craniofacial Research) and NIH grant RO–1 AR51598–01 (National Institute of Arthritis and Musculoskeletal Skin Diseases). We wish to acknowledge the help and support of the XLH Network http://www.xlhnetwork.org/ and in particular Dr Larry Winger (XLH group coordinator, England) and Dr Gerry Morrow (clinician, England). The views expressed in this material are those of the authors and do not reflect the official policy or position of the US Government, the Department of Defense, or the Department of the Air Force. The authors declare that there is no conflict of interest that could prejudice the impartiality of this scientific work.

References


